Medicare Enrolled

Dr. Noam Drazin, M.D.

Hematology & Oncology · Beverly Hills, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
200 N ROBERTSON BLVD, Beverly Hills, CA 90211
3109671884
In practice since 2006 (19 years)
NPI: 1952313520 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Drazin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Drazin? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Drazin

Dr. Noam Drazin is a hematology & oncology specialist in Beverly Hills, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Drazin performed 5,891 Medicare services across 542 unique beneficiaries.

Between the years covered by Open Payments, Dr. Drazin received a total of $1,522,106 from 70 pharmaceutical and/or device companies across 2292 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Drazin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 32% volume in CA $1,522,106 industry payments

Medicare Practice Summary

Medicare Utilization ↗
5,891
Medicare services
Top 32% in CA for hematology & oncology
542
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~310 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Epoetin alfa injection (Procrit) for anemia
An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis.
4,560 $6 $30
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
909 $102 $425
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
110 $8 $17
Telephone medical discussion, 21-30 minutes
A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone.
79 $101 $424
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
69 $13 $74
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
62 $131 $551
Venipuncture for blood collection
A procedure to draw blood from a vein for medical testing or analysis.
38 $80 $355
New patient office visit, complex (60-74 min) 35 $188 $722
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
29 $125 $596
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$1,522,106
Total received (2018-2024)
Avg $217,444/year across 7 years
Top 1% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
2,292
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,464,264 (96.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$46,284 (3.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,558 (0.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$180,270
2023
$200,940
2022
$209,640
2021
$262,472
2020
$151,266
2019
$259,645
2018
$257,873

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$115,201
Daiichi Sankyo Inc.
$57,767
Lilly USA, LLC
$7,135
Deciphera Pharmaceuticals Inc.
$42
Regeneron Healthcare Solutions, Inc.
$37
ARRAY BIOPHARMA INC
$34
Genentech USA, Inc.
$31
Incyte Corporation
$24
Top 3 companies account for 99.9% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$889,324
Lilly USA, LLC
$317,969
Amgen Inc.
$134,148
Daiichi Sankyo Inc.
$74,349
E.R. Squibb & Sons, L.L.C.
$30,651
Seagen Inc.
$29,853
Seattle Genetics, Inc.
$15,963
PFIZER INC.
$7,948
BeiGene USA, Inc.
$4,069
AbbVie Inc.
$2,867
Takeda Pharmaceuticals U.S.A., Inc.
$2,782
Janssen Biotech, Inc.
$2,495
Dova Pharmaceuticals
$1,527
Novartis Pharmaceuticals Corporation
$720
Merck Sharp & Dohme Corporation
$684
Incyte Corporation
$594
Genentech USA, Inc.
$590
Janssen Pharmaceuticals, Inc
$570
Celgene Corporation
$417
Astellas Pharma US Inc
$398
Taiho Oncology, Inc.
$342
AMAG Pharmaceuticals, Inc.
$341
Kite Pharma, Inc.
$271
GENZYME CORPORATION
$223
Deciphera Pharmaceuticals Inc.
$214
Puma Biotechnology, Inc.
$213
Pharmacyclics LLC, An AbbVie Company
$209
Eisai Inc.
$170
Gilead Sciences, Inc.
$159
Regeneron Healthcare Solutions, Inc.
$159
Bayer HealthCare Pharmaceuticals Inc.
$133
Alexion Pharmaceuticals, Inc.
$126
Myovant Sciences Inc.
$124
Merck Sharp & Dohme LLC
$109
GE HealthCare
$97
Global Blood Therapeutics, Inc.
$96
MEDIVATION FIELD SOLUTIONS LLC
$96
Rigel Pharmaceuticals, Inc.
$76
ARRAY BIOPHARMA INC
$74
MACROGENICS, INC.
$63
Boehringer Ingelheim Pharmaceuticals, Inc.
$61
EISAI INC.
$56
PUMA BIOTECHNOLOGY, INC.
$50
Novo Nordisk Inc
$46
JAZZ PHARMACEUTICALS INC.
$43
Otsuka America Pharmaceutical, Inc.
$43
Helsinn Therapeutics (U.S.), Inc.
$42
Pharmacyclics LLC, an AbbVie Company
$41
Myriad Genetic Laboratories, Inc.
$39
CSL Behring
$37
Ipsen Biopharmaceuticals, Inc
$32
INSYS Therapeutics Inc
$30
Stemline Therapeutics Inc.
$29
Kyowa Kirin, Inc.
$28
Octapharma USA, Inc.
$28
Biohaven Pharmaceutical Holding Company Ltd.
$26
Bayer Healthcare Pharmaceuticals Inc.
$25
Mirati Therapeutics, Inc.
$25
Teva Pharmaceuticals USA, Inc.
$25
Nestle HealthCare Nutrition Inc.
$23
AbbVie, Inc.
$23
SANOFI-AVENTIS U.S. LLC
$22
GE HEALTHCARE
$20
TerSera Therapeutics LLC
$19
Mylan Pharmaceuticals Inc.
$17
Fortovia Therapeutics, Inc.
$15
Shionogi Inc
$14
Exelixis Inc.
$13
Endo Pharmaceuticals Inc.
$12
Heron Therapeutics, Inc.
$9
Top 3 companies account for 88.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · Abraxane · Afstyla · Alecensa · Aliqopa · Aranesp · Avastin · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CERDELGA · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIQUIS · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EXKIVITY · Enhertu · Erleada · Esperoct · FASLODEX · FERAHEME · Fulphila · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Inrebic · JADENU · JAKAFI · Jivi · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MARGENZA · MEKINIST · MONJUVI · Mulpleta · NASCOBAL · NERLYNX · NINLARO · NURTEC ODT · Nerlynx · Neulasta · Novoeight · Nplate · OCTAGAM · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · POTELIGEO · PROMACTA · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYDAPT · Revlimid · SCEMBLIX · SOLIRIS · SPRYCEL · SUTENT · SYNDROS · Soltamox · Somatuline Depot · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VIZIMPRO · VYXEOS · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XTANDI · XYNTHA · Xermelo · Xtandi · Yescarta · ZENPEP · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in CA.

Looking for a hematology & oncology specialist in Beverly Hills?
Compare hematology & oncology specialists in the Beverly Hills area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
393
Per 100K population
4.0
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.8 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Drazin is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 1% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Drazin experienced with epoetin alfa injection (procrit) for anemia?
Based on Medicare claims data, Dr. Drazin performed 4,560 epoetin alfa injection (procrit) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Drazin receive payments from pharmaceutical companies?
Yes. Dr. Drazin received a total of $1,522,106 from 70 companies across 2,292 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Drazin's costs compare to other hematology & oncology specialists in Beverly Hills?
Dr. Drazin's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Drazin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →